PLK1 expression and KRAS mutations in colorectal cancer (CRC)


Priya Jayachandran, Andrew Elliott, Francesca Battaglin, Emil Lou, Wu Zhang, Shivani Soni, Hiroyuki Arai, Jingyuan Wang, Joshua Millstein, Albert Lockhart, W. Michael Korn, Heinz-Josef Lenz


  • A lack of increased PLK1 expression suggests similar potential for PLK1 inhibitors in KRAS-MT tumors compared to KRAS-WT.
  • Among PLK1 expression groups, proportionate increases in dMMR/MSI-H, TMB, and other immune related markers suggest a potential response to immunotherapy in tumors with increased PLK1 expression.
  • Combining immunotherapy with a PLK1 inhibitor might be a synergistic approach to increase sensitivity in PLK1-overexpressing CRC regardless of KRAS status.

Download Publication